Guest: Gregory A. Poland, M.D. (@drgregpoland)

Host: Amit K. Ghosh, M.D., M.B.A. (@AmitGhosh006)

SARS-CoV-2, as an RNA virus, has marked capacity for mutation and recombination events. How do we build an efficacious and safe vaccine against it? How could we safely speed up development? Is a vaccine neutralizing the spike protein enough? Gregory A. Poland, M.D., gives an update from the front lines of research on vaccine development and ongoing clinical trials. 

Tortoises, hares, and vaccines: A cautionary note for SARS-CoV-2 vaccine development

'I Have A Dream' Speech

Our 'Fierce Urgency of Now' — Secretary Kathleen Sebelius

King Legacy: 'Fierce Urgency of Now' Exists Today

AskMayoExpert COVID-19 Navigator resources:

This education is supported in part by an independent medical education grant from Pfizer Inc. and is in accordance with ACCME guidelines.

Click here to claim credit and view faculty disclosures. Select Register to begin the credit claim process.

Connect with Mayo Clinic School of Continuous Professional Development online at or on Twitter @MayoMedEd.


August 6, 2020

Created by

Mayo Clinic